
<DOC>
<DOCNO>WT01-B21-51</DOCNO>
<DOCOLDNO>IA087-000627-B019-42</DOCOLDNO>
<DOCHDR>
http://206.61.184.43:80/schaffer/hemp/medical/mjtouret.htm 206.61.184.43 19970122052743 text/html 13376
HTTP/1.0 200 OK
Date: Wednesday, 22-Jan-97 05:27:38 GMT
Server: WebSitePro/1.1f (S/N wpo-0deb)
Allow-ranges: bytes
Content-type: text/html
Last-modified: Saturday, 28-Dec-96 06:04:01 GMT
Content-length: 13158
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">

<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>Marijuana and Tourette's Syndrome</title>
<meta name="FORMATTER" content="Microsoft FrontPage 2.0">
</head>

<body stylesrc="../../../_private/schaffer_style.htm"
background="../../../images/whttxtr2.jpg" bgcolor="#F2F2F2">
<!--webbot bot="Include"
u-include="../../../_private/schaffer_logo.htm" tag="BODY"
startspan -->

<p align="center"><img src="../../../images/schlogo_small.gif"
align="bottom" width="583" height="38"> </p>
<!--webbot bot="Include" endspan i-checksum="1994" --><!--webbot
bot="Include"
u-include="../../../_private/sch_hemp_medical_navbar.htm"
tag="BODY" startspan -->

<p><a href="../../../toc.htm">Contents</a> | <a
href="../../../feedback.htm">Feedback</a> | <a
href="../../../search.htm">Search</a> </p>

<p><a href="../../../index.htm">DRCNet Library</a> | <a
href="../../index.HTM">Schaffer Library</a>&nbsp;| <a
href="../hempmenu.htm">Hemp (Marijuana)</a> | <a
href="medical.htm">Medical Information</a> </p>
<!--webbot bot="Include" endspan i-checksum="55454" -->

<hr>

<p><font size="3"></font>&nbsp;</p>

<p><font size="3">MARIJUANA AND TOURETTE'S SYNDROME</font></p>

<p><font size="3">&nbsp;</font></p>

<p><font size="3">Journal of Clinical Psychopharmacology, Vol.
8/No. 6, Dec 1988</font></p>

<p><font size="3">&nbsp;</font></p>

<p><font size="3">Editors:</font></p>

<p><font size="3">&nbsp;</font></p>

<p><font size="3">Although a variety of pharmacological agents
have been reported to</font></p>

<p><font size="3">attenuate symptoms of Tourette's syndrome (TS),
the pathophysiology of this</font></p>

<p><font size="3">disorder remains unknown. Apart from the
presence of disabling motor and</font></p>

<p><font size="3">vocal tics, TS patients often experience
behavioral disturbances including</font></p>

<p><font size="3">obsessive compulsive thoughts, anxiety,
depression, abnormal sleep</font></p>

<p><font size="3">disturbances. (1) Drug abuse to obtain relief
from the chronic anxiety may</font></p>

<p><font size="3">be common among these patients. (2) (3) We
recently encountered three</font></p>

<p><font size="3">patients with TS who experienced incomplete
responses to conventional</font></p>

<p><font size="3">anti-TS drugs but noted a significant
amelioration of symptoms when smoking</font></p>

<p><font size="3">marijuana.</font></p>

<p><font size="3">The first patient was a 15-year-old boy who, in
addition to motor</font></p>

<p><font size="3">tics, had obsessive compulsive and
self-mutilatory behavior improved with</font></p>

<p><font size="3">administration of imipramine (37.5 mg/day)
combined with the oral opiate</font></p>

<p><font size="3">receptor antagonist naltrexone (dose range 50
to 100 mg/day). During</font></p>

<p><font size="3">recreational use of marijuana (1 to 2
cigarettes/day), he noted general</font></p>

<p><font size="3">relaxation and marked lessening in his urge to
tic. According to the</font></p>

<p><font size="3">patient's mother, motor tics had decreased by
about 50% and there was also</font></p>

<p><font size="3">some reduction in the frequency of the
self-mutilatory behavior. The</font></p>

<p><font size="3">patients had been smoking marijuana for 4
weeks, and upon discontinuation,</font></p>

<p><font size="3">noted rebound exacerbation of symptoms within
12 hours.</font></p>

<p><font size="3">The second patient, age 17, had had severe
motor tics since the age</font></p>

<p><font size="3">of 7 years. He had frequent jerk-type movements
of his neck muscles</font></p>

<p><font size="3">associate with infrequent vocalizations during
stressful situations. His</font></p>

<p><font size="3">management had been difficult as he was unable
to tolerate haloperidol or</font></p>

<p><font size="3">clonidine. Administration of naltrexone (150
mg/day) reduced his anxiety</font></p>

<p><font size="3">level and the urge to tic; this was the only
drug he could tolerate. On</font></p>

<p><font size="3">several occasions, he had smoked marijuana and
noted generalized relaxation</font></p>

<p><font size="3">accompanied by reduction in the severity of the
motor tics and improvement</font></p>

<p><font size="3">in attention span. He volunteered that smoking
one cigarette reduced the</font></p>

<p><font size="3">frequency of his motor tics by about 60% to
70%, which was sustained over</font></p>

<p><font size="3">several hours. </font></p>

<p><font size="3">The third patient was a 39-year-old man who had
had symptoms of TS</font></p>

<p><font size="3">since the age of 9 years. His symptoms included
frequent jerking-type</font></p>

<p><font size="3">movements of his neck and upper extremity
muscles, facial grimacing,</font></p>

<p><font size="3">frequent blinking, and leg jerking.
Vocalizations were not noted except</font></p>

<p><font size="3">during extreme anxiety. In addition he was
troubled by chronic insomnia</font></p>

<p><font size="3">and hypersexuality. He reported no benefit from
haloperidol, clonidine, or</font></p>

<p><font size="3">benzodiazepines but experienced some relief
after consuming large amounts</font></p>

<p><font size="3">of ethanol. He also admitted that marijuana
smoking (1/2 to 1</font></p>

<p><font size="3">cigarette/day) produced relaxation with
subsequent reduction in the</font></p>

<p><font size="3">severity of the motor tics along with marked
attenuation of his</font></p>

<p><font size="3">hypersexuality. </font></p>

<p><font size="3">From 1842 to the turn of this century, several
reports in the</font></p>

<p><font size="3">literature have indicated that marijuana
smoking was used extensively as an</font></p>

<p><font size="3">analgesic, sedative, and hypnotic agent. (4)
Moreover, oral cannabis</font></p>

<p><font size="3">preparations were useful in the management of
diverse neurological</font></p>

<p><font size="3">conditions including convulsions and chorea.
(5) Much more recently it was</font></p>

<p><font size="3">reported anecdotally that patients with
dystonia improved with their</font></p>

<p><font size="3">alleged cannabis smoking. (6) The cannabis
constituent cannabidiol was</font></p>

<p><font size="3">reported efficacious in reducing symptoms of
dystonia. (7,8) and</font></p>

<p><font size="3">Huntington's chorea. (9) In experimental
animals, cannabidiol has been</font></p>

<p><font size="3">shown to exert anticonvulsant and antianxiety
properties and affect</font></p>

<p><font size="3">apomorphine-induced turning behavior in rats.
(10) The latter report</font></p>

<p><font size="3">suggested that cannabidiol exerts
antidyskinetic effects through modulation</font></p>

<p><font size="3">of striatal dopaminergic activity.
Tetrahudrocannabinol (THC, the active</font></p>

<p><font size="3">compound of marijuana) may exert GABA-ergic as
well as antiserotonergic</font></p>

<p><font size="3">effects. (11) A recent report has demonstrated
that THC reduces opiate</font></p>

<p><font size="3">receptor binding sites and modulates opiod
receptors in a noncompetitive</font></p>

<p><font size="3">manner. (12) THC may also exert effects on the
cholinergic system. (13)</font></p>

<p><font size="3">Considering evidence that marijuana may exert
effects on a large</font></p>

<p><font size="3">number of neurotransmitters, it is difficult to
speculate on its mode of</font></p>

<p><font size="3">action in attenuating symptoms of TS. It is
reasonable to assume that the</font></p>

<p><font size="3">effects of marijuana in TS may be largely
related to its anxiety-reducing</font></p>

<p><font size="3">properties, although a more specific
antidyskinetic effect cannot be</font></p>

<p><font size="3">excluded. Should marijuana compounds prove to
have specific actions in TS,</font></p>

<p><font size="3">chemical modifications which eliminate the
psychoactive properties while</font></p>

<p><font size="3">retaining the antiduskinetic effects (e.g.,
cannabidiol) could promise a</font></p>

<p><font size="3">new class of drugs useful in the management of
TS. Further studies are</font></p>

<p><font size="3">clearly needed in both the clinical and basic
laboratory realms to further</font></p>

<p><font size="3">characterize the effects of cannabinoids in TS.</font></p>

<p><font size="3">&nbsp;</font></p>

<p><font size="3">Reuven Sandyk, MD, MSc</font></p>

<p><font size="3">Gavin Awerbuch, MD</font></p>

<p><font size="3">University of Arizona</font></p>

<p><font size="3">Tucson, Arizona</font></p>

<p><font size="3">&nbsp;</font></p>

<p><font size="3">References</font></p>

<p><font size="3">&nbsp;</font></p>

<p><font size="3">1. Brunn RD. Gilles de la Tourette Syndrome: an
overview of clinical</font></p>

<p><font size="3">experience. J Am Acad Child Psychiatry 1984;23:
125-33.</font></p>

<p><font size="3">&nbsp;</font></p>

<p><font size="3">2. Mesulam MM. Cocaine and Tourette's syndrome.
N Engl J Med 1986; 315: </font></p>

<p><font size="3">398.</font></p>

<p><font size="3">&nbsp;</font></p>

<p><font size="3">3. Sandyk R, Gillman MD. Gilles de la Tourette
syndrome following</font></p>

<p><font size="3">alcohol withdrawal. Br J Addict 1985; 80:
213-4.</font></p>

<p><font size="3">&nbsp;</font></p>

<p><font size="3">4. Consroe P, Snider SR. Therapeutic potential
of cannabinoids in</font></p>

<p><font size="3">neurological disorders. In: Mechoulam R, ed.
Cannabinoids as therapeutic</font></p>

<p><font size="3">agents. Boca Raton, FL: CRC Press, 1986: 21-49.</font></p>

<p><font size="3">&nbsp;</font></p>

<p><font size="3">5. O'Shaughnessy R. On the preparation of the
indian hemp or gunjah </font></p>

<p><font size="3">(cannabis indica): the effects on the animal
system in health and their</font></p>

<p><font size="3">utility in the treatment of tetanus and other
convulsive diseases. Trans</font></p>

<p><font size="3">Med Phys Soc Bombay 1842; 8: 421-61.</font></p>

<p><font size="3">6. Marsden CD. Treatment of torsion dystonia.
In: Barbeau A, ed.</font></p>

<p><font size="3">Disorders of movement, current status of modern
therapy, Vol. 8. </font></p>

<p><font size="3">Philadelphia: Lippincott, 1981: 81-104.</font></p>

<p><font size="3">&nbsp;</font></p>

<p><font size="3">7. Snider SF, Consroe P. Treatment of Meige's
syndrome with cannabidiol. </font></p>

<p><font size="3">Neurology 1984; 34 (Suppl): 147.</font></p>

<p><font size="3">&nbsp;</font></p>

<p><font size="3">8. Consroe P, Sandyk R, Snider SR. Open label
evaluation of cannabidiol</font></p>

<p><font size="3">in dystonic movement disorder. Int J Neurosci
1986; 30: 277-80.</font></p>

<p><font size="3">&nbsp;</font></p>

<p><font size="3">9. Sandyk R, Consroe P, Stern LZ, Snider SR.
Effects of cannabidiol in</font></p>

<p><font size="3">Hungtington's disease. Neurology 1986; 36
(suppl): 342.</font></p>

<p><font size="3">&nbsp;</font></p>

<p><font size="3">10. Conti LH, Johannesen J, Musty RE, Consroe
P. Anti-dyskinetic effects</font></p>

<p><font size="3">of cannabidiol. Proceedings of the
International Congress on Marijuana. </font></p>

<p><font size="3">Melbourne, Australia: Melbourne University
Press 1987: 21.</font></p>

<p><font size="3">&nbsp;</font></p>

<p><font size="3">11. Revuelta AV, Cheney DL, Wood PL, Costa E.
Gabergic mediation in the</font></p>

<p><font size="3">inhibition of hippocampal acetylcholine
turnover rate elicited by</font></p>

<p><font size="3">delta-9-tetrahudrocannabidiol. J Clin Pharmacol
1979; 18: 525-30.</font></p>

<p><font size="3">&nbsp;</font></p>

<p><font size="3">12. Vaysse PJJ, Gardner EL, Zukin RS.
Modulation of rat brain opiod</font></p>

<p><font size="3">receptors by cannabinoids. J Pharmacol Exp Ther
1987; 241: 534-9.</font></p>

<p><font size="3">&nbsp;</font></p>

<p><font size="3">13. Revuelta AV, Moroni F, Cheney DL, Costa E.
Effect of cannabinoids on</font></p>

<p><font size="3">the turnover rate of acetylcholine in rat
hippocampus, striatum and cortex.</font></p>

<p><font size="3">Naunyn Schmiedebergs Arch Pharmacol 1978; 304:
107-11.</font></p>

<hr>
<!--webbot bot="Include"
u-include="../../../_private/sch_hemp_medical_navbar.htm"
tag="BODY" startspan -->

<p><a href="../../../toc.htm">Contents</a> | <a
href="../../../feedback.htm">Feedback</a> | <a
href="../../../search.htm">Search</a> </p>

<p><a href="../../../index.htm">DRCNet Library</a> | <a
href="../../index.HTM">Schaffer Library</a>&nbsp;| <a
href="../hempmenu.htm">Hemp (Marijuana)</a> | <a
href="medical.htm">Medical Information</a> </p>
<!--webbot bot="Include" endspan i-checksum="55454" -->
</body>
</html>
</DOC>